Advertisement

Picture Demy-Colton BioFuture 2021 NYC C Virtual Option 650x80px
Organisation › Details

Nabriva Therapeutics plc (Nasdaq: NBRV)

Nabriva Therapeutics is a biopharmaceutical company engaged in the research and development of new medicines to treat serious bacterial infections, with a focus on the pleuromutilin class of antibiotics. Nabriva Therapeutics’ medicinal chemistry expertise has enabled targeted discovery of novel pleuromutilins, including both intravenous and oral formulations. Nabriva Therapeutics’ lead product candidate, lefamulin, is a novel semi-synthetic pleuromutilin antibiotic with the potential to be the first-in-class available for systemic administration in humans. The company believes that lefamulin is the first antibiotic with a novel mechanism of action to have reached late-stage clinical development in more than a decade. Nabriva has announced positive topline data for lefamulin from the first of its two global, registrational Phase 3 clinical trials evaluating lefamulin in patients with moderate to severe community-acquired bacterial pneumonia (CABP). Nabriva Therapeutics believes lefamulin is well-positioned for use as a first-line empiric monotherapy for the treatment of moderate to severe CABP due to its novel mechanism of action, targeted spectrum of activity, resistance profile, achievement of substantial drug concentration in lung tissue and fluid, oral and IV formulations and a favorable tolerability profile. Nabriva Therapeutics is exploring potential further development of lefamulin for additional indications, including the treatment of acute bacterial skin and skin structure infections (ABSSSI), and is developing a formulation of lefamulin appropriate for pediatric use. Nabriva Therapeutics owns exclusive, worldwide rights to lefamulin, which is protected by composition of matter patents issued in the U.S., Europe and Japan. *

 

Period Start 2017-05-23 restructured
  Group Nabriva (Group)
  Predecessor Nabriva Therapeutics AG
Products Industry anti-infective drug
  Industry 2 lefamulin (BC-3781)
Person Person Schroeder, Ted (Nabriva 201807– CEO before Zavante Therapeutics + Cadence Pharmaceuticals + Élan)
     
Region Region Dublin
  Country Ireland, Republic of
  Street 25–28 North Wall Quay IFSC
  City Dublin 1
  Tel +353-1-649-2000
    Address record changed: 2020-12-02
     
Basic data Employees D: 101 to 500 (2019-01-31)
  Currency USD
  Annual sales 9,656,000 (revenues, total, consolidated (2018) 2018-12-31)
  Profit -114,780,000 (2018-12-31)
  Cash 102,003,000 (2018-12-31)
     
    * Document for �About Section�: Nabriva Therapeutics plc. (9/20/17). "Press Release: Nabriva Therapeutics to Present at the Cantor Fitzgerald Global Healthcare Conference". Dublin & King of Prussia, PA.
     
   
Record changed: 2021-02-26

Advertisement

Picture EBD Group Global Partnering Four Events One Price 650x80

More documents for Nabriva (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

Picture Berlin Partner Network in German Capital Region 650x80px




» top